[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2012DN01983A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01983A
IN2012DN01983A IN1983DEN2012A IN2012DN01983A IN 2012DN01983 A IN2012DN01983 A IN 2012DN01983A IN 1983DEN2012 A IN1983DEN2012 A IN 1983DEN2012A IN 2012DN01983 A IN2012DN01983 A IN 2012DN01983A
Authority
IN
India
Prior art keywords
pdgfrp
csf1r
epha2
vegfr2
kit
Prior art date
Application number
Other languages
English (en)
Inventor
Jiang Shan
Xing Xinglong
Wang Qishan
Kong Ren
Original Assignee
Ascepion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascepion Pharmaceuticals Inc filed Critical Ascepion Pharmaceuticals Inc
Publication of IN2012DN01983A publication Critical patent/IN2012DN01983A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN1983DEN2012 2009-08-24 2010-08-20 IN2012DN01983A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23627409P 2009-08-24 2009-08-24
PCT/CN2010/076199 WO2011023081A1 (fr) 2009-08-24 2010-08-20 Composés d'urée contenant un groupe hétéroaryle 5,6-bicyclique

Publications (1)

Publication Number Publication Date
IN2012DN01983A true IN2012DN01983A (fr) 2015-07-24

Family

ID=43627250

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1983DEN2012 IN2012DN01983A (fr) 2009-08-24 2010-08-20

Country Status (19)

Country Link
US (1) US8648086B2 (fr)
EP (1) EP2470533A4 (fr)
JP (1) JP2013502444A (fr)
KR (1) KR20120089459A (fr)
CN (1) CN102066372B (fr)
AU (1) AU2010289143A1 (fr)
BR (1) BR112012003462A2 (fr)
CA (1) CA2769151A1 (fr)
CO (1) CO6491087A2 (fr)
EA (1) EA201290073A1 (fr)
EC (1) ECSP12011691A (fr)
IL (1) IL218114A0 (fr)
IN (1) IN2012DN01983A (fr)
MA (1) MA33559B1 (fr)
MX (1) MX2012002317A (fr)
SG (1) SG178092A1 (fr)
TN (1) TN2012000042A1 (fr)
WO (1) WO2011023081A1 (fr)
ZA (1) ZA201200890B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004018A (es) 2008-10-14 2011-06-24 Ning Xi Compuestos y metodos de uso.
SG173867A1 (en) 2009-03-21 2011-10-28 Ning Xi Amino ester derivatives, salts thereof and methods of use
EP2611806A4 (fr) * 2010-09-01 2014-05-07 Ascepion Pharmaceuticals Inc Composés hétérocycliques enrichis en deutérium en tant qu'inhibiteurs de kinases
RU2606514C2 (ru) 2010-12-03 2017-01-10 Эпизайм, Инк. Замещенные пуриновые и 7-деазапуриновые соединения
CN102408426B (zh) * 2011-09-14 2013-07-10 湖南有色凯铂生物药业有限公司 取代的芳香脲类化合物及其作为抗癌药物的应用
FR2985257B1 (fr) * 2011-12-28 2014-02-14 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
CN103420895A (zh) * 2012-05-18 2013-12-04 苏州爱斯鹏药物研发有限责任公司 一种4-氨基吲哚的制备方法
US20150284422A1 (en) 2012-08-10 2015-10-08 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
EP2892536B1 (fr) 2012-09-06 2019-12-18 Epizyme, Inc. Méthode de traitement de la leucémie
CA2903303A1 (fr) 2013-03-15 2014-09-25 Epizyme, Inc. Procedes de synthese de composes de purine substitues
CN103613580B (zh) * 2013-09-03 2016-02-10 遵义医学院 用于抗肿瘤药物的3-羟基吲哚-2-酮类化合物或其药学上能够接受的盐
CN106279154A (zh) * 2016-08-02 2017-01-04 叶芳 一种7‑氮杂吲哚‑3‑甲醛的制备方法
CN108191874B (zh) * 2018-01-16 2019-11-29 成都施贝康生物医药科技有限公司 一种C-Kit抑制剂及其应用
CN111295380B (zh) * 2018-06-01 2020-11-20 杭州阿诺生物医药科技有限公司 一种高活性csf1r抑制剂化合物
WO2020033791A1 (fr) 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Compositions oligonucléotidiques pour cibler ccr2 et csf1r et leurs utilisations
WO2022123319A1 (fr) * 2020-12-11 2022-06-16 Ildong Pharmaceutical Co., Ltd. Agonistes de récepteurs opioïdes polarisés
AU2022292554A1 (en) 2021-06-14 2024-01-04 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3928177A1 (de) 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
TR199901710T2 (xx) 1997-01-23 1999-09-21 Smithkline Beecham Corporation IL-8 resept�r antagonistleri.
WO2000053591A1 (fr) * 1999-03-08 2000-09-14 Bayer Aktiengesellschaft Derives de la thiazolyluree et leur utilisation comme antiviraux
CO5190696A1 (es) 1999-06-16 2002-08-29 Smithkline Beecham Corp Antagonistas de los receptores il-8
US6525067B1 (en) * 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US20030158188A1 (en) 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
EP1537075B1 (fr) * 2002-09-05 2009-07-01 Neurosearch A/S Derives de diaryluree et leur utilisation comme bloqueurs de canaux chlorure
GB0226724D0 (en) 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7015233B2 (en) 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
GB0322016D0 (en) 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
BRPI0416656A (pt) * 2003-11-17 2007-01-16 Pfizer Prod Inc compostos de pirrolopirimidina úteis no tratamento do cáncer
DK1696920T3 (en) 2003-12-19 2015-01-19 Plexxikon Inc RELATIONS AND PROCEDURES FOR THE DEVELOPMENT OF LAW MODULATORS
JP2007518823A (ja) * 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
AU2005236002A1 (en) 2004-04-02 2005-11-03 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
WO2006009755A2 (fr) 2004-06-17 2006-01-26 Plexxikon, Inc. Composes modulant l'activite de c-kit
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
JP2008508304A (ja) 2004-07-27 2008-03-21 エスジーエックス ファーマシューティカルズ、インコーポレイテッド 縮合環ヘテロ環キナーゼ調節因子
EP2527339A1 (fr) 2004-11-24 2012-11-28 Abbott Laboratories Composés de chromanylurée inhibant le récepteur du sous-type 1 (VR1) du récepteur de vanilloïde et leurs utilisations
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
JP2008526988A (ja) 2005-01-14 2008-07-24 シージーアイ ファーマシューティカルズ，インコーポレーテッド キナーゼ活性モジュレーターとしての１，３−ジアリール置換尿素
JP2008531542A (ja) 2005-02-24 2008-08-14 ファイザー・プロダクツ・インク 抗癌剤として有用な二環式複素芳香族誘導体
US7777040B2 (en) 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
EP1885723A2 (fr) 2005-05-17 2008-02-13 Plexxikon, Inc. Composes modulant l'activite de c-kit et c-fms et utilisations
WO2007002325A1 (fr) 2005-06-22 2007-01-04 Plexxikon, Inc. Composes et methodes de modulation de la kinase et instructions afferentes
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
TW200745104A (en) * 2005-08-05 2007-12-16 Chugai Pharmaceutical Co Ltd Multikinase inhibitor
JP2007099642A (ja) * 2005-09-30 2007-04-19 Tsumura & Co 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物
CA2626593A1 (fr) 2005-10-28 2007-05-03 Abbott Laboratories Derives d'indazole inhibant le recepteur trpvl
CN101296928B (zh) * 2005-10-28 2011-01-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
ES2408318T3 (es) 2005-12-23 2013-06-20 Glaxosmithkline Llc Inhibidores de azaindol de las cinasas Aurora
WO2007090141A2 (fr) 2006-02-01 2007-08-09 Smithkline Beecham Corporation Composés chimiques
CN101058561B (zh) 2006-04-19 2011-01-26 苏州爱斯鹏药物研发有限责任公司 用于抑制蛋白激酶的二苯脲衍生物及其组合物和用途
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008079909A1 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
CN101636397B (zh) * 2007-04-13 2012-06-13 中国人民解放军军事医学科学院毒物药物研究所 脲类化合物、其制备方法及其医药用途

Also Published As

Publication number Publication date
IL218114A0 (en) 2012-04-30
EP2470533A4 (fr) 2013-01-23
MX2012002317A (es) 2012-06-25
US20120122895A1 (en) 2012-05-17
EP2470533A1 (fr) 2012-07-04
EA201290073A1 (ru) 2013-01-30
SG178092A1 (en) 2012-03-29
ECSP12011691A (es) 2012-04-30
CN102066372B (zh) 2014-09-17
CO6491087A2 (es) 2012-07-31
AU2010289143A1 (en) 2012-02-16
KR20120089459A (ko) 2012-08-10
MA33559B1 (fr) 2012-09-01
ZA201200890B (en) 2012-10-31
US8648086B2 (en) 2014-02-11
CN102066372A (zh) 2011-05-18
BR112012003462A2 (pt) 2016-02-23
TN2012000042A1 (en) 2013-09-19
CA2769151A1 (fr) 2011-03-03
JP2013502444A (ja) 2013-01-24
WO2011023081A1 (fr) 2011-03-03

Similar Documents

Publication Publication Date Title
IN2012DN01983A (fr)
MX2022002581A (es) Compuestos de benzimidazol como inhibidores de c-kit.
MX339899B (es) Compuestos de triazolopiridina como inhibidores de pim cinasa.
PH12014502573A1 (en) Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
MX355632B (es) Inhibidores de la trayectoria de señalización notch y uso de los mismos en el tratamiento de cánceres.
TN2011000673A1 (en) Bace inhibitors
NZ716392A (en) Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
MX2015010128A (es) Derivados de piridazinona macrociclicos.
MX2015009270A (es) Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
MX2016008110A (es) Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
MX2015001720A (es) Hetero-azepinonas sustituidas.
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
UA112795C2 (uk) Біциклічні піразинонові похідні
CL2011001947A1 (es) Compuestos derivados de fenil-{1,2,4}triazolo[1,5-a]piridin-fenilamino sustituidos, inhibidores de cinasa; utiles para tratar trastornos asociados con la permeabilidad vascular.
PH12015501038A1 (en) Inhibitors of iap
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
EA201400214A1 (ru) Антраниламидные соединения и их применение в качестве пестицидов
EA201170447A1 (ru) Производные изохинолинона в качестве антагонистов nk3
EA201400215A1 (ru) Антраниламидные соединения и их применение в качестве пестицидов
MX2010010000A (es) Derivados de 2-trifluorometilnicotinamida como agentes para aumentar el colesterol de lipoproteinas de alta densidad.
NZ630436A (en) Novel compounds as diacylglycerol acyltransferase inhibitors
ZA200705490B (en) Substituted benzimidazoles for treatment of histomoniasis